In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Sheds Light On Appropriate Frequency And Age For Colonoscopy

This article was originally published in The Gray Sheet

Executive Summary

Two studies in the May 24 Journal of the American Medical Association provide insight into how frequently colonoscopic cancer screening should occur and the age at which it should be discontinued, but do not get at the more basic question of whether the expensive procedure is effective in reducing colon cancer incidence or deaths, according to an accompanying editorial

You may also be interested in...



Stryker’s Sightline Purchase To Pay Off In 2007, Boost Endoscopy Division

Stryker's $140 mil. acquisition of endoscopic device firm Sightline Technologies will lead to increased revenue starting in 2007, according to CEO Steve MacMillan

FDA May Require Premarket Clearance For Exact Sciences’ PreGen-Plus

LabCorp will continue to market Exact Sciences' PreGen-Plus colorectal cancer screening assay pending further word from FDA, which has indicated that the diagnostic may require regulation as a medical device, Exact Sciences says

Immunochemical Colorectal Cancer Test An Accurate Adjunct – Lancet Study

The combination of guaiac and immunochemical fecal occult blood testing can reduce the need for colonoscopies by 30%, according to a Lancet study published Jan. 5

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel